Published 11/02/2009 by M2
ExonHit announces participation in MAPT study
Therapeutic and diagnostic company ExonHit Therapeutics (Paris: ALEHT) said today that, together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF), it will participate in the Multidomain Alzheimer Preventive Trial (MAPT).
The study's main objective is to assess the efficacy...
Share this
What others report on the same story